{"id":"bat4406f-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CD47 is a protein that inhibits phagocytosis, and by targeting it, BAT4406F Injection aims to enhance the body's ability to eliminate cancer cells. This mechanism is based on the principle of blocking the 'don't eat me' signal, allowing the immune system to recognize and destroy cancer cells more effectively.","oneSentence":"BAT4406F Injection is a monoclonal antibody targeting CD47.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:11.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06044350","phase":"PHASE2","title":"A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2023-08-01","conditions":"Optic Neuromyelitis Spectrum Disease","enrollment":162},{"nctId":"NCT04146285","phase":"PHASE1","title":"A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2020-09-01","conditions":"Neuromyelitis Optica Spectrum Disorders","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BAT4406F Injection","genericName":"BAT4406F Injection","companyName":"Bio-Thera Solutions","companyId":"bio-thera-solutions","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAT4406F Injection is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}